ClinicalTrials.gg
TerminatedNCT00930046Updated Apr 28, 2020Results posted

The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine

An interventional study of Ropivacaine wound catheter and Saline wound catheter in Obstruction of Pelviureteric Junction, sponsored by Boston Children's Hospital. Terminated at 2 sites in United States. Open to participants aged 3 Months to 14 Years. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
The institution transitioned from open surgical procedure to Robotic procedure

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
3 Months to 14 Years
Sex
All
01

Study summary

The investigators propose a prospective blinded randomized control trial (RCT) to assess the efficacy and safety of a simple method of continuous infusion of a local anesthetic, ropivacaine, via a surgical wound to control pain after ureteropelvic junction (UPJ) stenosis correction in children during the first 48 hrs after surgery. The investigators hypothesize that this technique will provide greater pain relief post-operatively and reduce the need for systemic opioid use along with a reduction in associated side effects of such analgesics.

Read the detailed description

The investigators hypothesize that continuous infusion of local anesthetic via a wound catheter would improve postoperative pain control after UPJ correction and diminish the adverse effects associated with current use of opioids, administered via epidural or systemic route, for the management of postoperative pain. The expected benefits from wound catheter infusion are reduction in postoperative opioids requirement thereby diminishing the associated side effects of sedation, respiratory depression, nausea, vomiting, and ileus which occur at an average rate of 50% in children and adolescents based on recent meta-analysis. It may also facilitate early oral intake, ambulation and early discharge from the hospital.

The current use of epidural indwelling catheters for analgesia is associated with 20-25% technical failure rate from catheter misplacement, occlusion, disconnect or dislodgement, premature discontinuation of analgesia due to opioid-related side effects, requires bladder catheterization, and local anesthetic induced weakness in the lower extremities that usually delays ambulation. The dose of local anesthetics infused via the epidural route is much larger than proposed via wound catheters and carries greater risks of systemic toxicity compared to infusion doses anticipated via wound catheter infusion. In addition, the use of opioids such as morphine or hydromorphone via the epidural indwelling catheters produce adverse effects similar to that of systemic opioids and require electronic and close nursing monitoring.

Study Design

The study will include patients, male and female, between the ages of 3 months to 14 years of all ethnic and race groups. Patients with a history of clinically significant cardiovascular, pulmonary, hepatic, renal, neurologic, psychiatric or metabolic disease will be excluded. After obtaining consent from a legal guardian, patients will be randomly assigned to the placebo or treatment group. Both groups will receive rescue opioids for postoperative pain management via either patient-controlled analgesia (PCA) or nurse-controlled analgesia (NCA) administration for younger patients. The intraoperative anesthetic management will be standardized in all patients.

The wound catheter (Soaker multi-orifice catheter approved by the FDA) will be placed at the completion of the surgery in the subcutaneous space parallel and proximal to the surgical incision by the surgeon. The Pain Treatment Service will manage postoperative pain with standardized protocols including infusion of ropivacaine via the wound catheter and administration of rescue opioids via PCA/NCA. Patients will be randomly assigned to receive infusions of either ropivacaine or saline via the wound catheters.

Outcome Measures

The primary outcome measure is the total amount of opioids consumed by patients in the treatment group compared to that consumed by the placebo groups, noting the potential opioid-sparing effect in the patients treated with the continuous wound catheters with ropivacaine versus saline in the placebo group. The secondary outcome measures include a composite pain assessment scale (FLACC), that can be used as a self-report or observation scale, incidence of opioid-related incidence of nausea, vomiting, sedation and respiratory depression, time to first feed (as a measure of return of bowel function), transition to oral analgesics, time to first ambulation and time to discharge from the hospital. Finally, any adverse outcomes related to local anesthetic infusion, catheter related infection and technical failure such as catheter occlusion and premature dislodgement will be recorded.

Patient Recruitment

Patients will be identified from the Urology Clinic scheduling office and recruited in the Pre-operative Anesthesia Clinic.

Data Collection

Outcome measure data will be recorded by nurses and physicians who are unaware of the randomization for 48hrs post-operatively. The following outcome measures will be recorded. The total amount of opioids consumed by all patients over the first 48hrs after surgery, The daily total amount and pattern of opioid use via a PCA or NCA pump will be recorded from the electronic medical record. The pain assessment scores and adverse effects of opioids and local anesthetic administration will be recorded by a standardized protocol. Other outcome measures include the incidence of emesis, time to first feed or oral intake, pain intensity assessment by self-report in older children and observation in younger children, and time to discharge.

Statistical Analysis

Power analysis indicated that 48 patients randomized equally to each group (n=24 per group) will provide 80% (alpha= 0.05, beta= 0.20) power to detect a 25% difference in total opioid usage during the first 48 hours postoperatively. Fisher's exact test will be used to compare binomial proportions of nausea/vomiting, sedation, respiratory depression, ileus, and proportion of patients requiring postoperative opioids. In addition, groups will be compared using Kaplan-Meier curves and will be constructed to model time to first oral intake with the log-rank test to compare groups and 95% confidence intervals derived using Greenwood's formula. A Uniform(0,1) random number generator will be used to determine treatment allocation and to minimize any covariate imbalances between the ropivacaine and saline groups. Two-tailed values of p\<0.05 will be regarded as statistically significant.

Summary

The investigators anticipate that the simple measure of wound catheter infusion with ropivacaine will demonstrate a significant safe and effective modality of analgesia in the postoperative period. If our results are valid, improved pain modulation with such a simple, low-tech modality of postoperative pain control (a) will require further investigation with a larger patient population including broader categories of surgical procedures to determine the limits of efficacy of such techniques in a particular surgical procedure, (b) may demonstrate statistically and clinically significant decreases in pain and decrease opioid demands, (c) may lessen time for recovery and side effects secondary to opioid use (d) offer significant cost-benefit for in-patient care relative to currently used modalities of epidural analgesia or systemic opioids for the management of postoperative pain in children undergoing UPJ correction and (e) compared to presently used epidural and PCA opioid analgesia, the wound catheter analgesia is expected to be less demanding on nurses and physicians (i.e. Pain Treatment Service), staff time, attention and need for close monitoring.

02

Conditions studied

  • Obstruction of Pelviureteric Junction

Keywords

  • ropivacaine
  • pediatric
  • children
  • continuous
  • wound
  • catheter
  • infusion
  • pyeloplasty
03

In context

Multicystic renal dysplasia, bilateral

26 studies on the registry are indexed under Multicystic renal dysplasia, bilateral; 9 are open to participants now.

This study's enrollment of 15 is below the median of 40 across 20 interventional studies indexed under Multicystic renal dysplasia, bilateral.

Browse Multicystic renal dysplasia, bilateral studies →

Lead sponsor

Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of UPJ stenosis requiring surgical repair
  • Ages 3 months to 14 years old
  • Guardians give consent and the child gives assent when appropriate
  • Both genders
  • All racial and ethnic groups

Exclusion criteria

Exclusion Criteria:

  • A history of chronic pain and/or use of chronic opioids and other analgesic(s)
  • If parents/patients or attending urologist request epidural analgesia or refuse to participate in the study
  • Impairment of cognition/neurologic, hepatic, renal, cardiovascular, endocrine, metabolic, and/or coagulation function
  • A history of any diagnosis of psychiatric disorders, including bipolar disorders by self-report or by guardian
  • A recent history of illicit chemical abuse within one week prior to surgical date
  • Participants known to be taking prescribed medications or over-the-counter medications known to affect pain perception such as central nervous system stimulants, hypnotics, sedatives, etc within 24 hours of planned surgical procedure
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    Ropivacaine group

    Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery

    Device: Ropivacaine wound catheter

  • Placebo comparator
    Normal Saline Group

    Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.

    Device: Saline wound catheter

Interventions

  • DeviceRopivacaine wound catheter

    19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.

    Also known as: ON-Q Catheter

  • DeviceSaline wound catheter

    19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure

    Also known as: ON-Q Catheter

06

What researchers measure

Primary outcomes

  1. Morphine

    Total amount of morphine used in the first 48hrs immediately after surgery

    Time frame: 48 hours

Secondary outcomes

  1. FLACC Pain Intensity [Faces Legs Activity Cry Consolability] 0-10 Points

    Observational FLACC pain intensity assessment tool that consists of observing the Faces Legs Activity Cry Consolability (FLACC) by the bedside nursing staff. This pain assessment tool is validated in non-verbal children and children at 7 years and younger. Minimum value is 0 and the maximum value is 10, where 0 represents no pain which is a better outcome.

    Time frame: 48 hours post-operatively

07

Results

Posted Apr 28, 2020

Participant flow

Participant flow — Overall Study
MilestoneRopivacaine GroupNormal Saline Group
Started87
Completed75
Not completed12
Withdrew: Wound catheter malfunctioned12

Outcome measures

PrimaryMorphine

Total amount of morphine used in the first 48hrs immediately after surgery

Time frame:
48 hours
Reported as:
Mean · mg/kg per 48 hours
Morphine
mg/kg per 48 hoursRopivacaine GroupNormal Saline Group
Morphine2.2 ± 1.83.5 ± 1.8
SecondaryFLACC Pain Intensity [Faces Legs Activity Cry Consolability] 0-10 Points

Observational FLACC pain intensity assessment tool that consists of observing the Faces Legs Activity Cry Consolability (FLACC) by the bedside nursing staff. This pain assessment tool is validated in non-verbal children and children at 7 years and younger. Minimum value is 0 and the maximum value is 10, where 0 represents no pain which is a better outcome.

Time frame:
48 hours post-operatively
Reported as:
Mean · score on a scale
FLACC Pain Intensity [Faces Legs Activity Cry Consolability] 0-10 Points
score on a scaleRopivacaine GroupNormal Saline Group
FLACC Pain Intensity [Faces Legs Activity Cry Consolability] 0-10 Points1.3 ± 0.71.9 ± 1.8

Adverse events

Collected over up to 48 hours post-operatively. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ropivacaine Group0/8 (0%)0/8 (0%)0/8 (0%)
Normal Saline Group0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ropivacaine GroupNormal Saline GroupTotal
<=18 years8715
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Ropivacaine GroupNormal Saline GroupTotal
Female549
Male336
Region of Enrollment
Region of Enrollment(participants)Ropivacaine GroupNormal Saline GroupTotal
United States8715
08

Study locations

2 sites
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2009 to primary completion in Sep 2011, 28 months.

Results were first posted in Apr 2020, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2009
First posted
Jun 30, 2009
StartActual
Apr 24, 2009
Primary completionActual
Sep 6, 2011
CompletionActual
Sep 6, 2011
Results first posted
Apr 28, 2020
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00930046
Responsible party
Navil Sethna (Senior Associate in Perioperative Anesthesia, Boston Children's Hospital) — Principal investigator
First posted
Jun 30, 2009
Start date
Apr 24, 2009
Primary completion
Sep 6, 2011
Completion
Sep 6, 2011
Results posted
Apr 28, 2020
Last update
Apr 28, 2020

Study contacts

Navil Sethna, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion